𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinising hormone-releasing hormone antagonist cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II

✍ Scribed by A. Jungwirth; J. Pinski; G. Galvan; G. Halmos; K. Szepeshazi; R.Z. Gai; K. Groot; M. Vadillo-buenfil; A.V. Schally

Book ID
117663823
Publisher
Elsevier Science
Year
1997
Tongue
English
Weight
966 KB
Volume
33
Category
Article
ISSN
0959-8049

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Luteinizing hormone-releasing hormone an
Luteinizing hormone-releasing hormone antagonist Cetrorelix (SB-75) and bombesin antagonist RC-3940-II inhibit the growth of androgen-independent PC-3 prostate cancer in nude mice
✍ Jungwirth, Andreas; Galvan, Georg; Pinski, Jacek; Halmos, Gabor; Szepeshazi, Kar πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 72 KB πŸ‘ 2 views

## Background: Hormones like bombesin (bn)/gastrin-releasing peptide (grp) and luteinizing hormone-releasing hormone (lh-rh) and growth factors such as epidermal growth factor (egf) might be involved in the relapse of prostate cancer under androgen ablation therapy. interference with receptors for

Inhibition of the growth of caki-I human
Inhibition of the growth of caki-I human renal adenocarcinoma in Vivo by luteinizing hormone-releasing hormone antagonist cetrorelix, somatostatin analog RC-160, and bombesin antagonist RC-3940-II
✍ Andreas Jungwirth; Andrew V. Schally; Gabor Halmos; Kate Groot; Karoly Szepeshaz πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 224 KB πŸ‘ 2 views

## Background: Metastatic or recurrent renal cell carcinoma (rcc) is a therapeutic challenge because it is resistant to chemotherapy and external radiotherapy. no uniformly effective therapeutic agents are available for the management of patients with rcc. hormones and growth factors may play a rol

Inhibition of growth of MDA-MB-468 estro
Inhibition of growth of MDA-MB-468 estrogen-independent human breast carcinoma by bombesin/gastrin-releasing peptide antagonists RC-3095 and RC-3940-II
✍ Zsuzsanna KahΓ‘n; Baodong Sun; Andrew V. Schally; JosΓ© M. Arencibia; Ren-Zhi Cai; πŸ“‚ Article πŸ“… 2000 πŸ› John Wiley and Sons 🌐 English βš– 133 KB

## BACKGROUND. The growth of breast carcinoma is promoted by autocrine growth factors such as the bombesin (BN)-like peptides and epidermal growth factor (EGF). The stimulatory action of BN-like peptides can be blocked by the use of BN/gastrin-releasing peptide (GRP) antagonists. ## METHODS. The